MUTUAL CONFIDENTIALITY AGREEMENTMutual Confidentiality Agreement • January 23rd, 2023 • Ipsen, S.A. • Pharmaceutical preparations
THIS MUTUAL CONFIDENTIALITY AGREEMENT (the “Agreement”) made as of June 10, 2022 (the “Effective Date”), is between Albireo Pharma, Inc., with a main address at 53 State Street, Boston, Massachusetts 02109 (“Albireo”) and Ipsen Pharma SAS with a main address at 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France (“Other Party”).
MUTUAL CONFIDENTIALITY AGREEMENTMutual Confidentiality Agreement • January 23rd, 2023 • Ipsen, S.A. • Pharmaceutical preparations
THIS MUTUAL CONFIDENTIALITY AGREEMENT (the “Agreement”) made as of January 17, 2022 (the “Effective Date”), is between Albireo Pharma, Inc. (“Albireo”) and Ipsen Bioscience, Inc. (“Ipsen”) and Albireo and Ipsen may be referred to herein individually as a “Party” and collectively as the “Parties”.
CONTINGENT VALUE RIGHTS AGREEMENT By and between IPSEN BIOPHARMACEUTICALS, INC., IPSEN PHARMA SAS and as Rights Agent Dated as of [●], 2023Contingent Value Rights Agreement • January 23rd, 2023 • Ipsen, S.A. • Pharmaceutical preparations • Delaware
CONTINGENT VALUE RIGHTS AGREEMENT, dated as of [●], 2023 (this “Agreement”), by and between Ipsen Biopharmaceuticals, Inc., a Delaware corporation (“Parent”), and, solely for purposes of Section 6.2, Section 6.3, Section 6.4 and Section 6.12, Ipsen Pharma SAS, a French société par actions simplifiée (“Guarantor”), and [●], a [●] [●], as the Rights Agent (the “Rights Agent”), in favor of each person who from time to time holds one or more contingent value rights to receive the Milestone Payment (as defined below) upon the satisfaction of the Milestone (as defined below) during the Milestone Period (as defined below) (each such contingent value right, a “CVR”), subject to the terms and conditions set forth herein.
